Ensuing GLP-1 RA clinical trials in pediatric patients with obesity, when combined with structured lifestyle programs, suggest that early GLP-1 RA therapy may provide even more robust clinically meaningful weight loss and the potential to reduce T2D risk [6,7,8,9]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.